By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Macquarie Capital today downgraded Illumina's stock to Underperform, saying the company faces substantial headwinds moving ahead, including cuts in academic and government funding, excess large-scale sequencing capacity, and an "at best" flat microarray business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.